<i id='260C5A7367'><strike id='260C5A7367'><tt id='260C5A7367'><pre id='260C5A7367'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Virginia high school admissions case could be legal follow 
Shifting the focus from loneliness to social health 
Trump demands the U.S. pay no more for drugs than other countries … again 
Kaiser's Risant Health gobbled up Geisinger. Who is next? 
Tori Bowie and the unacceptable rates of Black maternal death 
Innovation in antibiotics is ailing. 'Brain drain' may kill it
Virginia high school admissions case could be legal follow 
With trial win, GSK could get blood cancer drug back on market 
The Supreme Court will review a ruling striking down a domestic violence federal gun ban 
Let's speed up science by embracing open access publishing 
Dobbs anniversary: the lost opportunity of abortion as health care 
Intellia reports positive results for its CRISPR 
The Supreme Court will review a ruling striking down a domestic violence federal gun ban 
Ebola public health emergency is over, WHO declares 
ChatGPT in medicine: STAT answers readers' burning questions 
